Abstract
INTRODUCTION: New glucose-monitoring technologies have different cost-benefit profiles compared with traditional finger-prick tests, resulting in a preference-sensitive situation for patients. This study aimed to assess the relative value adults with diabetes assign to device attributes in two countries.
RESEARCH DESIGN AND METHODS: Adults with type 1 or 2 diabetes from the Netherlands (n=226) and Poland (n=261) completed an online discrete choice experiment. Respondents choose between hypothetical glucose monitors described using seven attributes: precision, effort to check, number of finger pricks required, risk of skin irritation, information provided, alarm function and out-of-pocket costs. Panel mixed logit models were used to determine attribute relative importance and to calculate expected uptake rates and willingness to pay (WTP).
RESULTS: The most important attribute for both countries was monthly out-of-pocket costs. Polish respondents were more likely than Dutch respondents to choose a glucose-monitoring device over a standard finger prick and had higher WTP for a device. Dutch respondents had higher WTP for device improvements in an effort to check and reduce the number of finger pricks a device requires.
CONCLUSION: Costs are the primary concern of patients in both countries when choosing a glucose monitor and would likely hamper real-world uptake. The costs-benefit profiles of such devices should be critically reviewed.
Original language | English |
---|---|
Article number | A4 |
Journal | BMJ Open Diabetes Research & Care |
Volume | 11 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2023 |
Bibliographical note
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Funding
This study formed part of the Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project. The PREFER project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115966). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations.
Funders | Funder number |
---|---|
Horizon 2020 Framework Programme | |
European Federation of Pharmaceutical Industries and Associations | |
Innovative Medicines Initiative | 115966 |
Keywords
- Adult
- Humans
- Patient Preference
- Netherlands/epidemiology
- Poland/epidemiology
- Diabetes Mellitus/epidemiology
- Glucose